BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29752717)

  • 21. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
    Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
    Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
    Katsumata N; Yasuda M; Takahashi F; Isonishi S; Jobo T; Aoki D; Tsuda H; Sugiyama T; Kodama S; Kimura E; Ochiai K; Noda K;
    Lancet; 2009 Oct; 374(9698):1331-8. PubMed ID: 19767092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
    Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer.
    Bun S; Yunokawa M; Ebata T; Shimomura A; Shimoi T; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Makino Y; Hayashi Y; Tamura K
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):745-52. PubMed ID: 27522647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
    Cesca M; Frapolli R; Berndt A; Scarlato V; Richter P; Kosmehl H; D'Incalci M; Ryan AJ; Giavazzi R
    Neoplasia; 2009 Nov; 11(11):1155-64. PubMed ID: 19881951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
    Fleming ND; Coleman RL; Tung C; Westin SN; Hu W; Sun Y; Bhosale P; Munsell MF; Sood AK
    Gynecol Oncol; 2017 Oct; 147(1):41-46. PubMed ID: 28774461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
    Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
    Ebata T; Yunokawa M; Bun S; Shimomura A; Shimoi T; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1283-1288. PubMed ID: 27832327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
    Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
    Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of bevacizumab and cisplatin on human lung adenocarcinoma A549/DDP xenografts in nude mice].
    Dai M; Luo RC; Zheng DY; Lü CW; Ding XM
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1402-5. PubMed ID: 17884788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
    Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
    J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of sensitivity to cisplatin by orobol is associated with increased mitochondrial cytochrome c release in human ovarian carcinoma cells.
    Isonishi S; Saitou M; Yasuda M; Ochiai K; Tanaka T
    Gynecol Oncol; 2003 Aug; 90(2):413-20. PubMed ID: 12893210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
    Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
    Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
    Ansaloni L; Coccolini F; Morosi L; Ballerini A; Ceresoli M; Grosso G; Bertoli P; Busci LM; Lotti M; Cambria F; Pisano M; Rossetti D; Frigerio L; D'Incalci M; Zucchetti M
    Br J Cancer; 2015 Jan; 112(2):306-12. PubMed ID: 25461804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.